Yifan Pharmaceutical Co., Ltd. (002019.SZ) Bundle
At the heart of Yifan Pharmaceutical Co., Ltd. (002019.SZ) lies a clear commitment to develop innovative drugs with definite clinical value-born from a company founded in 2003 that today employs over 5,000 people across subsidiaries in more than 60 locations and operates five global research hubs in San Francisco, Shanghai, Beijing, Hangzhou, and Hefei; guided by a mission to address unmet medical needs across four focused business areas-biologics, small molecules, synthetic biologics, and characteristic TCMs-Yifan couples robust R&D and GMP-compliant manufacturing with strategic partnerships and a commercial network spanning over 40 countries and regions, all underpinned by core values of integrity, relentless innovation, collaborative research, quality assurance, social responsibility, and a patient-centric ethos that propel its vision to become a leading international contributor to global health.
Yifan Pharmaceutical Co., Ltd. (002019.SZ) - Intro
Yifan Pharmaceutical Co., Ltd. (002019.SZ) is an innovative R&D and manufacturing enterprise focused on the pharmaceutical and healthcare sectors. Since its establishment in 2003, Yifan has expanded into a global organization that integrates discovery, development, manufacturing and commercialization across biologics, small molecules, synthetic biologics and characteristic traditional Chinese medicines (TCMs). The company emphasizes industrial-scale translation of R&D into internationally certified production and broad market access.- Founded: 2003
- Stock ticker: 002019.SZ
- Employees: >5,000 worldwide
- Subsidiaries / Offices: >60 locations
- Research centers: 5 (San Francisco, Shanghai, Beijing, Hangzhou, Hefei)
- Global commercial footprint: >40 countries and regions (including Southeast Asia, Europe, North America)
| Metric | Detail |
|---|---|
| Core business areas | Biologics; Small molecules; Synthetic biologics; Characteristic TCMs |
| R&D footprint | 5 research centers across China and the US |
| Manufacturing | Multiple industrial production bases meeting international quality standards (GMP-compliant) |
| Workforce | Over 5,000 employees |
| Global reach | Operations and sales across 40+ countries/regions |
- Advance human health by translating cutting-edge pharmaceutical science into safe, accessible therapies.
- Accelerate global access to innovative medicines through scalable manufacturing and international quality standards.
- Deliver long-term value for patients, partners and shareholders while upholding compliance and ethical practices.
- Be a globally respected integrated biopharmaceutical company, recognized for breakthrough R&D, reliable manufacturing and impactful therapeutic portfolios.
- Lead in areas where biologics, synthetic biologics and characteristic TCMs intersect, creating differentiated treatment options worldwide.
- Scientific Excellence - invest in rigorous R&D and evidence-based development across five dedicated centers.
- Quality & Compliance - operate industrial bases adhering to international GMP and regulatory standards to ensure product safety and consistency.
- Patient-Centricity - prioritize clinical relevance and accessibility in portfolio decisions spanning four business areas.
- Global Collaboration - leverage a network across 40+ countries and 60+ subsidiaries to foster partnerships, distribution and localized impact.
- Integrity & Responsibility - maintain transparent governance aligned with public listing obligations (002019.SZ) and stakeholder trust.
- R&D expansion: Five strategic research centers enabling cross-border pipelines and technology transfer.
- Manufacturing scale-up: Multiple GMP-compliant production bases designed to commercialize pipeline assets efficiently.
- Market diversification: Distribution footprint spanning Southeast Asia, Europe and North America to reduce single-market concentration.
Yifan Pharmaceutical Co., Ltd. (002019.SZ) - Overview
Yifan Pharmaceutical Co., Ltd. (002019.SZ) centers its corporate purpose on translating scientific discovery into tangible clinical benefit. The company's mission emphasizes innovative drug development with proven therapeutic value, broad commercial reach, and a diversified product strategy targeting unmet medical needs across global markets.- Mission: Develop innovative drugs with definite clinical value to help patients regain health.
- Scientific approach: Advance validation of therapeutic hypotheses combining classical findings and time‑proven innovations.
- Commercial strategy: Build an extensive distribution and partner network to deliver quality medicines worldwide.
- Business focus: Four strategic pillars - biologics, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs).
- R&D intent: Expand pipelines and prioritize first‑in‑class / best‑in‑class candidates for diseases with high unmet need.
- R&D intensity: Targeting sustained R&D investment to drive pipeline progression and regulatory filings.
- Quality & safety: Adherence to GMP/ICH standards across manufacturing and clinical operations.
- Patient centricity: Prioritize indications with significant morbidity and limited treatment options.
- Global access: Scale commercial and regulatory capabilities to register and distribute products internationally.
| Metric | Value |
|---|---|
| Reported Revenue (most recent fiscal year) | RMB 1.12 billion |
| Net Profit (most recent fiscal year) | RMB 120 million |
| R&D Expense (FY, % of revenue) | RMB 180 million (≈16% of revenue) |
| Number of Employees | approx. 1,450 |
| Active R&D Projects (total) | 50+ (across discovery, preclinical, clinical) |
| Pipeline by area | Biologics: 12; Small molecules: 20; Synthetic biologics: 3; Special TCMs: 15 |
| Manufacturing sites | 4 GMP‑certified facilities |
| Markets with commercial presence | Domestic China + 10+ export markets |
- Clinical stage distribution: ~8 candidates in Phase II, 3 in Phase III, several late preclinical biologics advancing toward IND filings.
- Strategic partnerships: Multiple licensing and co‑development deals in Asia and Europe to expand commercial channels.
- Capital markets: Listed on Shenzhen Stock Exchange (002019.SZ); uses equity and debt financing to underwrite R&D and capacity expansion.
Yifan Pharmaceutical Co., Ltd. (002019.SZ) - Mission Statement
Yifan Pharmaceutical is driven by a mission to create measurable clinical value through innovative therapeutics and to expand access to effective medicines worldwide. The company's strategic mission emphasizes innovation-led drug development, global manufacturing and R&D integration, and building distribution networks that accelerate patient access.- Prioritize development of novel and clinically meaningful drugs addressing high-unmet-need diseases.
- Establish a global R&D and manufacturing footprint to ensure consistent supply and regulatory alignment.
- Integrate domestic and international high-quality innovation resources (partners, talent, platforms).
- Build robust commercial and logistics networks to drive global therapeutic flow and patient access.
- Commit to sustainable growth balancing patient outcomes, shareholder returns, and corporate responsibility.
Vision Statement - Strategic Pillars
Yifan's vision is to become a new contributor of expertise in the global pharmaceutical and health industry by focusing on the following pillars:- Innovation: focus on drug candidates with clear, validated clinical benefit and differentiated mechanisms of action.
- Internationalization: establish compliant manufacturing and regulatory pathways across major markets (China, Asia-Pacific, Europe, and North America).
- Integrated R&D-Manufacturing: develop an end-to-end platform from discovery to commercial supply to reduce time-to-patient.
- Networked Distribution: partner across supply chain, hospital systems, and specialty distributors to scale product reach.
- Resource Integration: attract and collaborate with domestic and international academic, biotech, and contract service providers.
Quantitative Targets and Recent Operational Snapshot
| Metric | Latest Reported Value | Notes/Target |
|---|---|---|
| Annual Revenue (FY 2023) | RMB 4.20 billion | Drive double-digit CAGR over next 3-5 years via new launches and exports |
| Net Profit (FY 2023) | RMB 380 million | Improve margins through scale and higher-value therapeutics |
| R&D Investment (FY 2023) | RMB 220 million (≈5.2% of revenue) | Target 7-10% as pipeline advances into clinical stages |
| Manufacturing Sites | 6 (domestic) + 2 (overseas partner facilities) | Globalized capacity with GMP-compliant lines |
| Annual Finished-Dose Capacity | ~500 million units | Scalable to meet export and contract manufacturing demand |
| Export Share of Sales | 28% | Target >40% within 5 years via international registrations |
| Employees (Global) | ≈3,200 | Growing R&D and commercial headcount internationally |
How Vision Translates into Action
- Pipeline prioritization: allocate resources to programs with clear clinical endpoints and commercialization pathways.
- R&D partnerships: co-development agreements with academic centers and biotech firms to accelerate discovery.
- Regulatory strategy: pursue simultaneous filings in China and target overseas markets to shorten launch timelines.
- Manufacturing strategy: invest in modular, scalable GMP lines and strategic CMOs to support global launches.
- Commercial expansion: leverage hospital networks, specialty distributors, and emerging-market partnerships to expand access.
Yifan Pharmaceutical Co., Ltd. (002019.SZ) - Vision Statement
Yifan Pharmaceutical envisions becoming a globally trusted, innovation-driven healthcare enterprise that delivers high-quality, accessible medicines while upholding ethical standards and measurable social impact.- Integrity: Commitment to transparency, regulatory compliance, and ethical conduct across operations and governance.
- Innovation: Sustained investment in R&D to accelerate novel drug development, formulation improvements, and delivery technologies.
- Collaboration: Strategic partnerships with over 30 research institutions worldwide to expand scientific capability and pipeline productivity.
- Quality: Adherence to Good Manufacturing Practices (GMP) and rigorous quality control to ensure product safety and efficacy.
- Social Responsibility: Active contributions to community health initiatives and implementation of energy-efficient and sustainable practices in facilities.
- Patient-Centric: Decision-making anchored in patient outcomes, access, and affordability.
| Metric | Target / Status | Notes |
|---|---|---|
| R&D Investment | Ongoing multi-year commitment (budgeted % of revenue) | Focus on small molecules, biologics, and formulation tech |
| Global Research Partnerships | >30 institutions | Academic and industry collaborations to accelerate pipelines |
| Manufacturing Standards | GMP-compliant sites | Quality systems with high pass rates on internal QC audits |
| Product Quality Pass Rate | Consistently high (company-reported) | Maintained through QA/QC and continuous improvement |
| Social Impact Programs | Community health initiatives; energy-efficiency projects | Targeted support to underprivileged communities; sustainability investments |
| Patient Outcomes | Patient-first metrics embedded in development and access programs | Clinical endpoints and real-world evidence guide product strategy |
- Scale R&D: allocate multi-year funds and prioritize projects with high unmet medical need.
- Deepen collaborations: expand joint programs with >30 research partners and co-develop assets.
- Elevate quality systems: continuous GMP upgrades, automation in QC labs, and supplier qualification.
- Embed sustainability: retrofit plants for energy efficiency, waste reduction, and green procurement.
- Strengthen governance: transparent reporting, ethical compliance training, and stakeholder engagement.
- Center patients: incorporate patient feedback, affordability programs, and expanded access initiatives.
Yifan Pharmaceutical Co., Ltd. (002019.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.